SCHEMBL4872415

SCHEMBL4872415

O=C(Cc1ccnc2ccccc12)c1cccc(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.43
TGFBR1 P36897 1/20 0.39
ALDH1A1 P00352 3/20 0.38
PDE4A P27815 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
HTT P42858 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
HIF1A Q16665 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
PABPC1 P11940 1/20 0.37
EIF4H Q15056 1/20 0.37
KDM5A P29375 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233274 0.86 CYP1A2 (0.55) CYP1A2LOXL2ALDH1A1PDE4AADORA2A
SCHEMBL5236988 0.84 CYP1A2 (0.49) CYP1A2LOXL2ALDH1A1PDE4AADORA2A
SCHEMBL5236887 0.84 CYP1A2 (0.49) CYP1A2LOXL2TGFBR1ALDH1A1PDE4A
SCHEMBL5235225 0.84 CYP1A2 (0.49) CYP1A2LOXL2TGFBR1ALDH1A1PDE4A
SCHEMBL29959459 0.84 CYP1A2 (0.49) CYP1A2LOXL2TGFBR1ALDH1A1PDE4A
SCHEMBL29959944 0.82 CYP1A2 (0.47) CYP1A2LOXL2TGFBR1ALDH1A1PDE4A
SCHEMBL5234356 0.82 CYP1A2 (0.47) CYP1A2LOXL2TGFBR1ALDH1A1PDE4A
SCHEMBL4872056 0.81 CYP1A2 (0.55) CYP1A2LOXL2ALDH1A1HTTLMNA
SCHEMBL5231886 0.81 MGAM (0.53) CYP1A2LOXL2ALDH1A1SMN1; SMN2CYP3A4
SCHEMBL5235242 0.81 CYP1A2 (0.46) CYP1A2LOXL2TGFBR1ALDH1A1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365066-B2 Pyrazolopyridine derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-04-29 US disclosed
EP-1543001-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2007-08-15 EP disclosed
EP-1397364-B1 NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS LILLY CO ELI (US) 2007-07-25 EP disclosed
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents BEIGHT DOUGLAS W 2005-10-06 US disclosed
EP-1543001-A1 NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS ELI LILLY AND COMPANY (US) 2005-06-22 EP disclosed
WO-2004026871-A1 NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS ELI LILLY AND COMPANY (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents TGFB2, TGFB1, TGFBR1 CYP1A2 4047/4885LOXL2 2538/4885TGFBR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.